Rigel Pharmaceuticals, Inc. (RIGL)
NASDAQ: RIGL · Real-Time Price · USD
17.09
-0.12 (-0.70%)
Dec 20, 2024, 4:00 PM EST - Market closed
Rigel Pharmaceuticals Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for RIGL stock have an average target of 34.8, with a low estimate of 20 and a high estimate of 57. The average target predicts an increase of 103.63% from the current stock price of 17.09.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for RIGL stock from 5 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 2 | 2 | 2 | 2 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Hold Maintains $15 → $25 | Hold | Maintains | $15 → $25 | +46.28% | Dec 10, 2024 |
| B. Riley Securities | B. Riley Securities | Hold Maintains $27 → $20 | Hold | Maintains | $27 → $20 | +17.03% | Dec 10, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $57 | Strong Buy | Reiterates | $57 | +233.53% | Dec 10, 2024 |
| B. Riley Securities | B. Riley Securities | Hold Maintains $17 → $27 | Hold | Maintains | $17 → $27 | +57.99% | Dec 6, 2024 |
| Piper Sandler | Piper Sandler | Hold Maintains $15 → $23 | Hold | Maintains | $15 → $23 | +34.58% | Nov 14, 2024 |
Financial Forecast
Revenue This Year
172.49M
from 115.78M
Increased by 48.98%
Revenue Next Year
197.38M
from 172.49M
Increased by 14.43%
EPS This Year
0.29
from -1.44
EPS Next Year
1.00
from 0.29
Increased by 240.09%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 180.0M | 208.9M | 247.6M | |||
| Avg | 172.5M | 197.4M | 230.7M | |||
| Low | 162.9M | 180.4M | 213.7M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 55.4% | 21.1% | 25.4% | |||
| Avg | 49.0% | 14.4% | 16.9% | |||
| Low | 40.7% | 4.6% | 8.3% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 0.55 | 1.53 | 3.46 | |||
| Avg | 0.29 | 1.00 | 1.95 | |||
| Low | 0.09 | 0.52 | 0.95 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | 420.6% | 247.2% | |||
| Avg | - | 240.1% | 95.9% | |||
| Low | - | 77.2% | -4.6% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.